PhRMA on the State of the Union Address

Washington, D.C. (January 29, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement:

"President Obama’s address comes at a time when America’s biopharmaceutical research companies are bringing pioneering new medicines to patients, supporting high-value American jobs and helping strengthen local communities and our national economy. Continued progress – the kind that President Obama urged for last night – is only possible, however, if we fully embrace innovation.

Rx Minute: Statins Value to Society & Risk Factors Linked to Alzheimer's

A recent article published in Health Affairs highlights the remarkable impact of cholesterol-lowering drugs known as statins on the treatment of cardiovascular disease in the U.S.

Real Change for Patients with GI Cancer

11.17.14 | By

“Unless someone like you cares a whole awful lot, nothing is going to get better. It’s not.” Real change and progress, as Dr. Seuss suggests, starts with passionate individuals who want to make a difference. This is obvious from the dedicated researchers around the world working tirelessly to find new treatments that help patients with devastating diseases like gastrointestinal (GI) cancers.

Working Together to Stop Ebola in its Tracks

11.13.14 | By

The fantastic news came yesterday that Dr. Craig Spencer, the last patient in the U.S. with Ebola, has been cured. While this development certainly inspires hope, there is still much to be done in West Africa before we can celebrate the end of this dangerous disease that has already taken nearly 5,000 lives.

Week in Review: Access, Patients, Part D, Oh My

10.17.14 | By

Thanks in large part to innovative new treatments, now more than ever, patients can live longer, healthier lives. But in order for this to be possible, access to needed medicines is critical.

Five Things You Might Not Know About Medicare Part D

10.15.14 | By

Another Medicare open enrollment period begins today, Wednesday, October 15, and runs through Sunday, December 7. During open enrollment seniors and individuals with disabilities can evaluate their Medicare plan choices to make sure they’re still right for them, compare options and make changes for the new year. One thing beneficiaries evaluate during open enrollment is their prescription drug coverage. Here are five things you might not know about Medicare Part D:

Week in Review: Innovation and the Promise of Hope

10.10.14 | By

We often use the word “innovation” in Catalyst posts and on social media. To many, “innovation” may seem like just another buzzword, but to the biopharmaceutical industry it is the definition of hope. It is the hope that we can help patients live longer and healthier lives through, in large part, the development of new treatments.

Attention Overdue for Devastating Brain Disorders

10.08.14 | By

Mental Illness Awareness Week, which takes place the first full week of October, is an opportunity to raise awareness of mental illness and make progress in eliminating stigmas that discourage people from seeking care and support.  In the guest commentary below, Husseini K. Manji, MD, FRCPC, Global Head of Neuroscience for Janssen Research & Development LLC, a Johnson & Johnson Company, addresses the significant toll of mental illness.

ICYMI: Debunking Myths about Cancer Care in the United States

10.07.14 | By

Cancer is a devastating diagnosis and it’s hard to find someone who hasn’t been touched by the disease.  However, given its complexity, the facts about cancer care are often misconstrued.

Week in Review: Staying Informed Is Critical to Long-Term Health

09.26.14 | By

Helping patients understand and access high quality health care options is a central tenet of our industry. Today, more than ever, it’s essential that every member of the health care ecosystem move forward with this guiding objective in mind.

Pages

Subscribe to RSS - Opinion